Chronic Spontaneous Urticaria | Practical Pearls
Dermatologists need to be more visible in treating chronic spontaneous urticaria (CSU), says Dr. Adam Friedman, co-chair of the ODAC Dermatology, Aesthetic & Surgical Conference. Next Steps in Derm, in partnership with ODAC, interviewed Dr. Friedman, who shared what to consider when approaching a hive or hive-like patient. Hear the burden that patients with CSU face. Find out the first-line tr …
Dermatologists need to be more visible in treating chronic spontaneous urticaria (CSU), says Dr. Adam Friedman, co-chair of the ODAC Dermatology, Aesthetic & Surgical Conference. Next Steps in Derm, in partnership with ODAC, interviewed Dr. Friedman, who shared what to consider when approaching a hive or hive-like patient. Hear the burden that patients with CSU face. Find out the first-line tr … Continue reading "Chronic Spontaneous Urticaria | Practical Pearls"
WebMD recently posted an article, “Got a Zit, Eat Your Salmon,” which highlighted a study in the Journal of Cosmetic Dermatology on the role omega-3 fatty acids may play in preventing and treating acne. Should dermatologists address omega-3 fatty acid supplementation with their acne patients? What’s the latest in diet and acne?
For an expert’s take, I reached out to Vivian Shi, MD, di … 
Inpatient dermatologic consultations require expert care to make a prompt and accurate diagnosis. For best practices, Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Olayemi Sokumbi, a dermatologist and dermatopathologist with Mayo Clinic. Watch as Dr. Sokumbi shares the three categories you need to consider in your initial exam of an … 
During the 2024 Pigmentary Disorders Exchange Symposium, expert dermatologists discussed and shed light on the evolving therapeutic landscape of pigmentary disorders. They addressed key advances, challenges, and gaps in current knowledge. The panel, which was moderated by Dr. Pearl Grimes, featured Dr. John Harris, Dr. Thierry Passeron, and Dr. Ariel Kauvar.
Dr. Harris kicked off the panel disc … 
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … 